Skip to content

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Oncology · The big question

Colorectal Cancer Prepares to Spread Earlier Than We Thought

The emergence of metastasis in colorectal cancer

Editorial illustration for The emergence of metastasis in colorectal cancer
Editorial illustration

Summary

For anyone diagnosed with cancer, the most dangerous moment is when the disease begins to spread to new areas of the body, a process known as metastasis. Scientists have long wondered exactly when and how a localized tumor gains the ability to travel. In a new study looking at colorectal cancer, researchers made a surprising discovery. They found that tumors actually develop the necessary tools to spread much earlier than previously believed.

By studying patient samples and miniature lab-grown tumors called organoids, the research team looked at how tumor cells behave at a microscopic level. They discovered that many early-stage tumors adopt a highly flexible condition called an oncofetal state. Normally, this shapeshifting ability is only seen in advanced, late-stage cancers. But the researchers found that these flexible cancer cells were already gathering at the edges of early tumors. There, they mingle with normal connective tissue cells known as fibroblasts, which actively encourage the cancer cells to become even more adaptable and ready to move.

However, simply having these flexible cells is not enough to guarantee the cancer will spread, since not all early-stage tumors actually go on to metastasize. The researchers investigated what pushes the tumor over the edge. They ruled out new genetic mutations as the trigger. Instead, their findings suggest that a cancer cell's ability to hide from the immune system might be the final key to unlocking its deadly spread.

Why it matters.

This research shifts how we think about the timeline of colorectal cancer. If tumors gather the ingredients for metastasis early in their development, doctors might eventually be able to identify which early-stage cancers pose the highest risk of spreading. This could lead to more personalized treatment plans, where high-risk patients receive more aggressive therapies right from the start. Furthermore, knowing that immune evasion is the likely trigger for metastasis opens up exciting avenues for drug development, potentially allowing us to stop cancer from spreading by stripping away its microscopic camouflage.

It is important to note that this research is still in its early phases. The study relied on advanced laboratory profiling of cells rather than clinical trials, and it does not yet provide specific statistical patient outcomes. Large-scale human studies will be needed to fully validate these findings and translate them into everyday medical practice.

From the source

The story in numbers.

Types of biological models profiled (organoids and primary tumors)
2
Additional genomic events driving the metastatic process
0
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Oncology

Targeted Drug Spares Lymphoma Patients from Stem Cell Transplants

Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body. A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening. The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.

PubMed2 min read
Oncology

New nanoparticle tech breaks down tumor shields to boost immunity

Tumors have a sneaky way of hiding from the body's immune system. They wrap themselves in a dense, sugary protective coating known as the glycocalyx. This shield is packed with mucins, which are thick proteins that physically block immune cells and modern cancer treatments from reaching the target. While scientists have discovered a bacterial enzyme called StcE that can chew through this sticky barrier, using it as a drug has been difficult. Injecting the free enzyme directly into the body causes unwanted toxic side effects and triggers severe immune reactions. To solve this problem, researchers engineered a clever delivery system using cell membrane fusion nanovesicles, which are essentially microscopic bubbles made from natural cell materials. They equipped these tiny delivery vehicles with both the barrier-breaking StcE enzyme and specialized targeting molecules called CD47 nanobodies. These nanobodies act like a homing device that seeks out cancer cells. By using this biomimetic delivery platform, the enzyme successfully digests the protective sugary shield precisely at the tumor site, avoiding the widespread toxicity and safety issues of the free enzyme. With the barrier cleared away, the immune system gets a much clearer shot at the tumor. The researchers found that removing the mucin shield allowed the nanobodies to bind tightly to the cancer cells, sounding the alarm for the body's natural defenses. The treatment successfully suppressed tumor growth and stopped the cancer from spreading by radically remodeling the environment around the tumor, bringing in a flood of protective immune cells.

PubMed2 min read
Oncology

Merck's Targeted Cancer Therapy Shines in Global Trial

A pharmaceutical company named Merck is testing a new cancer treatment called Sac-TMT. This medicine is an antibody-drug conjugate, or ADC. You can think of an ADC as a guided missile for cancer cells. It uses a targeting system to seek out a specific protein called TROP2, which is found on the surface of many tumors, and then delivers a toxic payload directly to the cancer. In a recent global trial focused on advanced endometrial cancer, Sac-TMT successfully delayed the disease from worsening and helped patients live longer when compared to standard chemotherapy. The therapy proved effective for a particularly vulnerable group of patients. These individuals had already seen their cancer advance despite receiving previous treatments, including platinum-based chemotherapy and immunotherapy. This endometrial cancer study is just the beginning. It marks the first results from a massive late-stage clinical testing program that includes 17 different trials. Moving forward, researchers will evaluate how well Sac-TMT works against a variety of other tumor types, including breast and lung cancers. While the early news is highly encouraging, there are some important caveats to keep in mind. Merck noted that the drug's safety profile looks consistent with earlier tests, showing no unexpected side effects. However, the company has not yet released the specific numbers behind their findings. They have simply announced that the results were statistically significant and clinically meaningful, meaning we will need to wait for the full data to understand exactly how much benefit the drug provides.

BioPharma Dive2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗